Katelyn is a reporter with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

Apple’s iOS 27 update focuses on faster performance, Siri AI, Liquid Glass controls, expanded Apple Intelligence, and new family safety tools. Apple’s iOS 27 looks less like a redesign and more like a ...

If you've ever wanted to integrate OpenAI's ChatGPT features into your Java programs, you'll be happy to learn that Spring AI has made the process easier than ever. And it's not just easier to connect ...

Proteins are far more than nutrients we track on a food label. Present in every cell of our bodies, they work like nature's molecular machines. They walk, stretch, bend, and flex to do their jobs, ...

AI success depends on whether enterprise data is ready, reachable, and close enough to the workloads that need it. In this eSpeaks episode, Dell Technologies’ Vrashank Jain explains why fragmented ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

Claude will automatically generate interactive visuals based on your conversation, or you can ask it directly, too. Claude will automatically generate interactive visuals based on your conversation, ...

The Random Sequence Generator is a free online tool designed to help you easily generate synthetic biological sequences, including DNA, RNA, and proteins. These sequences are applicable to a variety ...

Microsoft’s Windows 11 Insider Preview Build 26220.7961 for 25H2 fixes File Explorer flashes, adds voice typing for renaming, and restores Administrator Protection. Microsoft has rolled out Windows 11 ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...